Choosing the right pulmonary delivery platform is a critical decision for early-phase innovators. Each approach offers unique advantages and challenges, impacting formulation, device selection, patient adherence, and regulatory pathways. On this episode we are joined by industry experts Carolyn Berg, Danforth Miller, Alan Watts and Phil Kuehl, who provide insights into the questions that need to be addressed by drug developers when considering pulmonary delivery and the different routes of administration (nebulized vs. dry powder). For more on the pulmonary delivery please visit https://international-pharma.com/ and explore our archived issues.